GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (BOM:532296) » Definitions » Cyclically Adjusted Revenue per Share

Glenmark Pharmaceuticals (BOM:532296) Cyclically Adjusted Revenue per Share : ₹442.84 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Glenmark Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2024 was ₹106.997. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹442.84 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Glenmark Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 5.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Glenmark Pharmaceuticals was 7.80% per year. The lowest was 7.40% per year. And the median was 7.60% per year.

As of today (2024-06-05), Glenmark Pharmaceuticals's current stock price is ₹1120.05. Glenmark Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₹442.84. Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 2.53.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Glenmark Pharmaceuticals was 2.62. The lowest was 0.59. And the median was 1.36.


Glenmark Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Glenmark Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 334.78 357.35 387.31 419.34 442.84

Glenmark Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 419.34 433.14 438.84 441.84 442.84

Competitive Comparison of Glenmark Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Glenmark Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Glenmark Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=106.997/153.0345*153.0345
=106.997

Current CPI (Mar. 2024) = 153.0345.

Glenmark Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 54.445 94.103 88.541
201409 61.658 96.780 97.497
201412 62.363 96.780 98.612
201503 64.447 97.163 101.506
201506 58.829 99.841 90.172
201509 72.763 101.753 109.434
201512 71.271 102.901 105.994
201603 77.964 102.518 116.381
201606 67.674 105.961 97.738
201609 76.982 105.961 111.181
201612 87.259 105.196 126.941
201703 86.013 105.196 125.128
201706 82.519 107.109 117.901
201709 78.790 109.021 110.598
201712 76.908 109.404 107.579
201803 79.624 109.786 110.990
201806 75.491 111.317 103.783
201809 89.999 115.142 119.617
201812 88.879 115.142 118.129
201903 89.534 118.202 115.918
201906 80.870 120.880 102.382
201909 97.986 123.175 121.739
201912 93.467 126.235 113.310
202003 96.125 124.705 117.962
202006 81.811 127.000 98.582
202009 103.011 130.118 121.153
202012 97.853 130.889 114.409
202103 100.236 131.771 116.411
202106 104.367 134.084 119.117
202109 110.747 135.847 124.759
202112 111.274 138.161 123.253
202203 104.945 138.822 115.689
202206 96.354 142.347 103.588
202209 105.704 144.661 111.822
202212 108.542 145.763 113.957
202303 104.712 146.865 109.111
202306 118.151 150.280 120.317
202309 111.855 151.492 112.994
202312 87.174 152.924 87.237
202403 106.997 153.035 106.997

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Glenmark Pharmaceuticals  (BOM:532296) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1120.05/442.84
=2.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Glenmark Pharmaceuticals was 2.62. The lowest was 0.59. And the median was 1.36.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Glenmark Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Pharmaceuticals (BOM:532296) Business Description

Traded in Other Exchanges
Address
Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (BOM:532296) Headlines

No Headlines